Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 1

Status

Sponsor Class

OTHER 92 INDUSTRY 6 OTHER_GOV 3 NIH 2 UNKNOWN 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Inoperable œsophageal Cancer 1

Interventions

Cisplatin 118 Radiotherapy 114 Cyclophosphamide 93 Paclitaxel 85 Gemcitabine 74 Carboplatin 68 Filgrastim 60 Doxorubicin 57 Vincristine 56 Etoposide 56 Docetaxel 56 Fluorouracil 51 Cytarabine 41 Prednisone 40 Methotrexate 40 Leucovorin 39 Dexamethasone 37 Capecitabine 36 Irinotecan 35 Rituximab 29 Oxaliplatin 28 Granulocyte Colony-Stimulating Factor 27 Cetuximab 26 Bevacizumab 26 durvalumab 24 Temozolomide 24 Radiotherapy, Intensity-Modulated 24 Peripheral Blood Stem Cell Transplantation 24 Magnetic Resonance Spectroscopy 24 Surgical Procedures, Operative 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NETWORK × Chemoradiotherapy × Clear all

NCT03437200 2023-02-21

CRUCIAL

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated

Inoperable œsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡